Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) on April 17, 2007.

One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to trea
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
(Date:9/17/2014)... Historically, spaceflight has been reserved for the very ... meet the highest physical and psychological standards to ... the advent of commercial spaceflight, average people can ... has had very little information about what medical ... in the spaceflight environment, as most medical conditions ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy and ... get the answer by reading Per Wickstrom’s latest blog post. ... business plan and a business strategy are both strategic – ... way I view it is that a business plan is ... two.” , According to the blog post, a business ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... University,s Physical Activity and Public Health Laboratory, active commuting ... can be an easy, effective and efficient way to ... Wittman, a K-State senior in kinesiology, Olathe, worked with ... of kinesiology, on the active commuting research. The project ...
... April 13 Mylan Inc. (Nasdaq: MYL ... banker,Andrew G. Cuneo as vice president of Global Business ... and strategic,efforts in close alignment with the company,s executive ... Chairman and CEO Robert J. Coury said: "Drew brings ...
... 13 Lionbridge,Technologies, Inc. (Nasdaq: ... testing,and development services today announced an alliance ... Enterprise Content Management (ECM) software,designed to ensure ... management solutions for pharmaceutical companies and other,organizations. ...
... could one day quickly detect if treatment is working, study ... technique that can detect subtle changes in cancer cells contained ... tissue may one day be used by doctors to better ... , "Currently, we don,t know what,s going on in a ...
... Though a high-fiber diet has long been considered good ... Medical College of Georgia researchers have discovered a reason ... Researchers report in the April issue of Cancer ... butyrate, a metabolite produced by fiber-eating bacteria in the ...
... 15th, there will be a,Capitol Hill briefing called ... and Mental Illness." Author and award winning ... HELP USA,Lamp Community, the National Alliance on Mental ... H.O.M.E. have join forces to host this,important briefing. ...
Cached Medicine News:Health News:Survey research looks at attitudes, obstacles to walking and biking to work 2Health News:Survey research looks at attitudes, obstacles to walking and biking to work 3Health News:Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development 2Health News:Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies 2Health News:A Drop of Blood May Help Assess Cancer Therapy 2Health News:Colon cancer shuts down receptor that could shut it down 2Health News:Colon cancer shuts down receptor that could shut it down 3Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 2Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: